Free Trial
NASDAQ:GDRX

GoodRx Q3 2026 Earnings Date & Estimates

GoodRx logo
$3.50 -0.07 (-1.83%)
As of 12:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GoodRx is estimated to report Q3 2026 earnings on Tuesday, November 17, 2026, after market closes.

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes

What Analysts Expect from GoodRx in Q3 2026

GoodRx is expected to post earnings of $0.0758 per share on revenue of $202.98 million. In the same quarter a year earlier GoodRx reported $0.08 per share on revenue of $196.03 million. GoodRx last reported on August 5, 2026, posting $0.08 per share and beating the $0.0797 consensus estimate. GoodRx has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.0758
Expected Revenue
$202.98 million
Prior-Year EPS
$0.08
Prior-Year Revenue
$196.03 million
Expected EPS Growth
-5.2%
Expected Revenue Growth
+3.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.08 (Beat by +$0.0003)
Last Quarter Revenue
$200.41 million
EPS Beat Rate
2 of last 8 quarters

GoodRx Q3 2026 Earnings FAQ

GoodRx (NASDAQ:GDRX) is estimated to report Q3 2026 earnings on Tuesday, November 17, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

GoodRx's Q3 2026 earnings conference call is scheduled for Wednesday, November 25, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect GoodRx to post earnings of $0.0758 per share for Q3 2026.

The consensus revenue estimate for GoodRx is $202.98 million for Q3 2026.

GoodRx Earnings Headlines

Financial Contrast: GoodRx (GDRX) & Its Rivals
GoodRx stock rises on Google Cloud healthcare AI partnership
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More GoodRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GoodRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GoodRx and other key companies, straight to your email.

About GoodRx

GoodRx (NASDAQ:GDRX) operates a digital healthcare platform that helps consumers in the United States compare prescription medication prices at pharmacies. Its website and mobile app provide free price comparisons and discounts that consumers can use when paying for eligible prescriptions.

The company also offers subscription services, including GoodRx Gold, and provides access to telehealth and other care services through GoodRx Care. Its platform connects consumers with pharmacies and healthcare providers, while its services for pharmaceutical companies include programs that help make medications and savings offers available to patients.

Founded in 2011, GoodRx is based in Santa Monica, California. The company’s business focuses on the U.S. healthcare market.

View GoodRx Profile